Aurinia Pharmaceuticals Inc. (AUPH) reported a dramatic financial turnaround for the nine months ended September 30, 2025 (Q3 FY2025).
Financial Performance & Profitability: Total revenue reached \(205.9M, driven by Net Product Sales of LUPKYNIS, which grew 24% year-to-date to \)197.2M. The company achieved Net Income of \(76.4M (up from \)4.3M in the prior year) and Income from Operations of \(71.7M (vs. a \)3.0M loss). Diluted EPS was \(0.55. Operating Cash Flow surged to \)90.0M, primarily used for capital return. Expense optimization was key, with SG&A costs cut substantially (\(72.5M vs. \)135
...